Repligen Corporation – NASDAQ:RGEN
Repligen stock price today
$123.5
-22.03
-15.14%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Repligen stock price monthly change
+15.58%
month
Repligen stock price quarterly change
+15.58%
quarter
Repligen stock price yearly change
-20.78%
year
Repligen key metrics
Market Cap | 8.07B |
Enterprise value | 9.34B |
P/E | 52.27 |
EV/Sales | 11.66 |
EV/EBITDA | 34.46 |
Price/Sales | 11.78 |
Price/Book | 4.94 |
PEG ratio | 1.19 |
EPS | 0.26 |
Revenue | 607.45M |
EBITDA | 27.33M |
Income | 14.84M |
Revenue Q/Q | -17.14% |
Revenue Y/Y | -21.90% |
Profit margin | 23.2% |
Oper. margin | 28.03% |
Gross margin | 56.85% |
EBIT margin | 28.03% |
EBITDA margin | 4.5% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeRepligen stock price history
Repligen stock forecast
Repligen financial statements
Average Price Target
$201.67
Potential upside: 63.29%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 159.16M | 20.06M | 12.61% |
|---|---|---|---|
| Sep 2023 | 141.19M | 18.17M | 12.87% |
| Dec 2023 | 155.74M | -25.48M | -16.37% |
| Mar 2024 | 151.34M | 2.09M | 1.38% |
| Jun 2023 | 2549003000 | 578.07M | 22.68% |
|---|---|---|---|
| Sep 2023 | 2514129000 | 525.57M | 20.9% |
| Dec 2023 | 2824411000 | 853.20M | 30.21% |
| Mar 2024 | 2849269000 | 878.66M | 30.84% |
| Jun 2023 | 34.46M | 64.83M | -8.82M |
|---|---|---|---|
| Sep 2023 | 39.23M | -8.77M | -778K |
| Dec 2023 | 29.06M | -169.90M | 268.12M |
| Mar 2024 | 44.70M | -8.36M | -8.97M |
Repligen alternative data
| Aug 2023 | 2,025 |
|---|---|
| Sep 2023 | 2,025 |
| Oct 2023 | 2,025 |
| Nov 2023 | 2,025 |
| Dec 2023 | 2,025 |
| Jan 2024 | 2,025 |
| Feb 2024 | 2,025 |
| Mar 2024 | 1,783 |
| Apr 2024 | 1,783 |
| May 2024 | 1,783 |
| Jun 2024 | 1,783 |
| Jul 2024 | 1,783 |
Repligen other data
100.00%
+15.85%
of RGEN is owned by hedge funds
391
-45
49.78M
+1.59M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Feb 2024 | 0 | 5373 |
| Mar 2024 | 0 | 20224 |
| May 2024 | 0 | 20072 |
| Jun 2024 | 4815 | 0 |
| Aug 2024 | 0 | 11613 |
| Sep 2024 | 0 | 22191 |
| Nov 2024 | 0 | 24246 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | HUNT ANTHONY director | Common Stock | 11,808 | $33.87 | $399,937 | ||
Option | HUNT ANTHONY director | Stock Option (Right to Buy) | 11,808 | $33.87 | $399,937 | ||
Option | HUNT ANTHONY director | Common Stock | 24,246 | $33.87 | $821,212 | ||
Sale | HUNT ANTHONY director | Common Stock | 24,246 | $139.67 | $3,386,439 | ||
Option | HUNT ANTHONY director | Stock Option (Right to Buy) | 24,246 | $33.87 | $821,212 | ||
Option | MUIR GLENN P director | Common Stock | 19,000 | $36.29 | $689,510 | ||
Option | MUIR GLENN P director | Stock Option (Right to Buy) | 19,000 | $36.29 | $689,510 | ||
Option | HUNT ANTHONY director | Common Stock | 10,000 | $33.87 | $338,700 | ||
Sale | HUNT ANTHONY director | Common Stock | 1,495 | $143.77 | $214,936 | ||
Sale | HUNT ANTHONY director | Common Stock | 9,369 | $144.88 | $1,357,381 |
| Patent |
|---|
Application Filling date: 24 May 2022 Issue date: 8 Sep 2022 |
Grant Filling date: 8 Sep 2020 Issue date: 6 Sep 2022 |
Grant Filling date: 8 Sep 2020 Issue date: 30 Aug 2022 |
Application Filling date: 16 Feb 2022 Issue date: 25 Aug 2022 |
Application Filling date: 26 Apr 2022 Issue date: 11 Aug 2022 |
Application Filling date: 5 Apr 2022 Issue date: 21 Jul 2022 |
Grant Filling date: 20 Sep 2018 Issue date: 19 Jul 2022 |
Grant Filling date: 14 Aug 2020 Issue date: 12 Jul 2022 |
Application Filling date: 9 Mar 2022 Issue date: 23 Jun 2022 |
Application FLUID FLOW MONITORING ASSEMBLY INCLUDING A FLOW SENSOR HOUSING REMOVABLY SECURED TO A FLEXIBLE CONDUIT THAT ENCAPSULATES THE REMOVABLE SENSOR Filling date: 8 Feb 2022 Issue date: 26 May 2022 |
| Quarter | Transcript |
|---|---|
| Q1 2024 1 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 21 Feb 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 31 Oct 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 2 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Anthony J. Hunt (1964) Chief Executive Officer, Pres & Director | $1,110,000 |
| Mr. Jon K. Snodgres (1966) Chief Financial Officer | $693,790 |
| Mr. Ralf Kuriyel (1959) Senior Vice President of R&D | $645,250 |
Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing
Avantor: Promising Long-Term Buy With Potential For Opportunistic Entry
Repligen: Exclusive Partnerships And Innovation Set To Drive Growth
Charles River Laboratories International: A Great Business At A Decent Price
Ranking The 10 Largest Biotechs By Pipeline
Repligen: Life Sciences Tools' Best Near-Cap Gain Buy
Repligen: Now Best Biotech Nearby Cap-Gain Prospect
The Correction In Biopharmaceutical Stocks Is Likely Over
Revisiting Repligen
-
What's the price of Repligen stock today?
One share of Repligen stock can currently be purchased for approximately $123.5.
-
When is Repligen's next earnings date?
Unfortunately, Repligen's (RGEN) next earnings date is currently unknown.
-
Does Repligen pay dividends?
No, Repligen does not pay dividends.
-
How much money does Repligen make?
Repligen has a market capitalization of 8.07B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 20.31% to 638.76M US dollars.
-
What is Repligen's stock symbol?
Repligen Corporation is traded on the NASDAQ under the ticker symbol "RGEN".
-
What is Repligen's primary industry?
Company operates in the Healthcare sector and Medical - Instruments & Supplies industry.
-
How do i buy shares of Repligen?
Shares of Repligen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Repligen's key executives?
Repligen's management team includes the following people:
- Mr. Anthony J. Hunt Chief Executive Officer, Pres & Director(age: 61, pay: $1,110,000)
- Mr. Jon K. Snodgres Chief Financial Officer(age: 59, pay: $693,790)
- Mr. Ralf Kuriyel Senior Vice President of R&D(age: 66, pay: $645,250)
-
How many employees does Repligen have?
As Jul 2024, Repligen employs 1,783 workers.
-
When Repligen went public?
Repligen Corporation is publicly traded company for more then 39 years since IPO on 29 Apr 1986.
-
What is Repligen's official website?
The official website for Repligen is repligen.com.
-
Where are Repligen's headquarters?
Repligen is headquartered at Building 1, Waltham, MA.
-
How can i contact Repligen?
Repligen's mailing address is Building 1, Waltham, MA and company can be reached via phone at +7 812500111.
-
What is Repligen stock forecast & price target?
Based on 3 Wall Street analysts` predicted price targets for Repligen in the last 12 months, the avarage price target is $201.67. The average price target represents a 63.29% change from the last price of $123.5.
Repligen company profile:
Repligen Corporation
repligen.comExchange:
NASDAQ
Full time employees:
1,783
Industry:
Medical - Instruments & Supplies
Sector:
Healthcare
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Building 1
Waltham, MA 02453
Waltham, MA 02453
CIK: 0000730272
ISIN: US7599161095
CUSIP: 759916109
